- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
OncoCyte Corp (OCX)
OncoCyte Corp stock price live, this page displays NASDAQ OCX stock exchange data. View the OCX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the OncoCyte Corp real time stock price chart below.
What Is the OncoCyte Corp Stock Price Today?
The OncoCyte Corp stock price today is 2.790.
What Is the Stock Symbol for OncoCyte Corp?
The stock symbol for OncoCyte Corp is "OCX."
What Stock Exchange Does OncoCyte Corp Trade On?
OncoCyte Corp is listed and trades on the NASDAQ stock exchange.
Is OncoCyte Corp a Good Stock to Buy?
Determining whether OncoCyte Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OCX quote. (ISIN: US68235C2061)
What Is the OncoCyte Corp Stock Price Today?
The OncoCyte Corp stock price today is 2.790.
What Is the Stock Symbol for OncoCyte Corp?
The stock symbol for OncoCyte Corp is "OCX."
What Stock Exchange Does OncoCyte Corp Trade On?
OncoCyte Corp is listed and trades on the NASDAQ stock exchange.
Is OncoCyte Corp a Good Stock to Buy?
Determining whether OncoCyte Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OCX quote. (ISIN: US68235C2061)
2.790
+0.190(+7.31%)
Closed·
After Hours
2.800+0.010(+0.358%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.600
2.860
52 wk Range
1.922
4.750
OCX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
OCX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.6002.860
52 wk Range
1.9224.750
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OCX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
4.417
Upside
+58.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
OncoCyte Corp Company Profile
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
OncoCyte Corp Earnings Call Summary for Q1/2025
- Q1 pharma services revenue beat expectations at $2.1M, driven by a late-quarter order; stock fell 2.09% in regular trading
- Strong cash position of $33M; negative free cash flow of $6.2M aligns with quarterly target
- FDA submission planned for end of 2024, with approval expected in early 2026 for transplant rejection testing
- Strategic pivot towards transplant rejection testing and oncology diagnostics; potential corporate name change forthcoming
- Analyst consensus optimistic with price targets ranging from $4.00 to $5.00 per share
Last Updated: 13/05/2025, 07:50 am
Read Full TranscriptCompare OCX to Peers and Sector
Metrics to compare | OCX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOCXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −2.2x | −0.5x | |
PEG Ratio | −0.04 | −0.01 | 0.00 | |
Price/Book | 7.3x | 2.6x | 2.6x | |
Price / LTM Sales | 19.3x | 26.1x | 2.9x | |
Upside (Analyst Target) | 55.7% | 570.4% | 51.4% | |
Fair Value Upside | Unlock | −8.4% | 9.5% | Unlock |
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.417
(+58.30% Upside)
Earnings
Latest Release
Mar 24, 2025
EPS / Forecast
-1.93 / -1.12
Revenue / Forecast
1.49M / 750.00K
People Also Watch
FAQ
What Is the OncoCyte (OCX) Stock Price Today?
The OncoCyte stock price today is 2.79
What Stock Exchange Does OncoCyte Trade On?
OncoCyte is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for OncoCyte?
The stock symbol for OncoCyte is "OCX."
What Is the OncoCyte Market Cap?
As of today, OncoCyte market cap is 74.36M.
What Is OncoCyte's Earnings Per Share (TTM)?
The OncoCyte EPS (TTM) is -3.35.
From a Technical Analysis Perspective, Is OCX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.